MRNA Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 0.7% compared to Moderna's net margin of 16.61%. Moderna's return on equity of -17.44% beat Gilead Sciences's return on equity of 0.64%.

Moderna has a consensus price target of $74.19, signalling upside risk potential of 56.09%. On the other hand Gilead Sciences has an analysts' consensus of $98.88 which suggests that it could grow by 9.11%. Given that Moderna has higher upside potential than Gilead Sciences, analysts believe Moderna is more attractive than Gilead Sciences.

Moderna has a beta of 1.597, which suggesting that the stock is 59.715% more volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.179, suggesting its less volatile than the S&P 500 by 82.12%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.4% to investors and pays a quarterly dividend of $0.77 per share. Moderna pays -- of its earnings as a dividend. Gilead Sciences pays out 67.24% of its earnings as a dividend. Gilead Sciences's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna quarterly revenues are $1.9B, which are smaller than Gilead Sciences quarterly revenues of $7.5B. Moderna's net income of $13M is lower than Gilead Sciences's net income of $1.3B. Notably, Moderna's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 1,007.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.64x versus 4.01x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 0.7% compared to Moderna's net margin of 8.48%. Moderna's return on equity of -17.44% beat Eli Lilly and's return on equity of 66.4%.

Moderna has a consensus price target of $74.19, signalling upside risk potential of 56.09%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 27.25%. Given that Moderna has higher upside potential than Eli Lilly and, analysts believe Moderna is more attractive than Eli Lilly and.

Moderna has a beta of 1.597, which suggesting that the stock is 59.715% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.729%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.67% to investors and pays a quarterly dividend of $1.30 per share. Moderna pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna quarterly revenues are $1.9B, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Moderna's net income of $13M is lower than Eli Lilly and's net income of $970.3M. Notably, Moderna's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 83.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.64x versus 17.11x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 0.7% compared to Moderna's net margin of 18.95%. Moderna's return on equity of -17.44% beat Merck &'s return on equity of 29.26%.

Moderna has a consensus price target of $74.19, signalling upside risk potential of 56.09%. On the other hand Merck & has an analysts' consensus of $128.73 which suggests that it could grow by 27.43%. Given that Moderna has higher upside potential than Merck &, analysts believe Moderna is more attractive than Merck &.

Moderna has a beta of 1.597, which suggesting that the stock is 59.715% more volatile than S&P 500. In comparison Merck & has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.989%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.09% to investors and pays a quarterly dividend of $0.81 per share. Moderna pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

Moderna quarterly revenues are $1.9B, which are smaller than Merck & quarterly revenues of $16.7B. Moderna's net income of $13M is lower than Merck &'s net income of $3.2B. Notably, Moderna's price-to-earnings ratio is -- while Merck &'s PE ratio is 21.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.64x versus 4.07x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 0.7% compared to Moderna's net margin of 25.23%. Moderna's return on equity of -17.44% beat Pfizer's return on equity of 4.63%.

Moderna has a consensus price target of $74.19, signalling upside risk potential of 56.09%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 17.45%. Given that Moderna has higher upside potential than Pfizer, analysts believe Moderna is more attractive than Pfizer.

Moderna has a beta of 1.597, which suggesting that the stock is 59.715% more volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.19% to investors and pays a quarterly dividend of $0.42 per share. Moderna pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Moderna quarterly revenues are $1.9B, which are smaller than Pfizer quarterly revenues of $17.7B. Moderna's net income of $13M is lower than Pfizer's net income of $4.5B. Notably, Moderna's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.64x versus 2.60x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.